The Clinical Utility of Liposomal Doxorubicin in Recurrent Ovarian Cancer
- 1 May 2001
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 81 (2), 206-212
- https://doi.org/10.1006/gyno.2000.5980
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999
- Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens.Journal of Clinical Oncology, 1998
- Topotecan in Platinum- and Paclitaxel-Resistant Ovarian CancerGynecologic Oncology, 1997
- A call for change in anticancer drug evaluationEuropean Journal Of Cancer, 1997
- Doxorubicin in sterically stabilized liposomesNature, 1996
- Doxorubicin Encapsulated in Liposomes Containing Surface‐Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS‐Related Kaposi's SarcomaThe Journal of Clinical Pharmacology, 1996
- c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast CancerNew England Journal of Medicine, 1994
- Overexpression of the Oncogene c-erb B2 in Primary Ovarian CancerInternational Journal of Gynecological Pathology, 1994
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Reporting results of cancer treatmentCancer, 1981